Literature DB >> 15693083

Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis.

Tatjana Klatt1, Qin Ouyang, Thomas Flad, Ina Koetter, Hans-Jörg Bühring, Hubert Kalbacher, Graham Pawelec, Claudia A Müller.   

Abstract

OBJECTIVE: To investigate control of Epstein-Barr virus (EBV) infection in rheumatoid arthritis (RA) by comparing the frequency phenotypes and function of peripheral CD8+ EBV-peptide antigen-specific T cells in patients with RA and healthy longterm carriers of EBV.
METHODS: The frequency of interferon-g (IFN-g)-producing HLA-A2 or HLA-B8-restricted EBV-reactive CD8+ T cells in peripheral blood mononuclear cells (PBMC) from 49 RA patients and 26 healthy EBV carriers was evaluated in Elispot assays with 12 lytic/latent peptide epitopes. Direct staining with HLA-peptide tetramers containing 3 of these peptides was performed for comparison. The phenotype and function of these T cells was determined by FACS and cytotoxicity testing.
RESULTS: IFN-g production patterns in Elispot assays revealed that EBV-specific CD8+ T cells were directed predominantly against the lytic epitopes A2/GLC and B8/RAK and to a minor extent to all the other lytic and latent epitopes tested, with no significant differences of the frequencies in patients and controls. However, although similar frequencies of CD8+ T cells stained with A2/GLC or B8/RAK tetramers in both groups, the fraction of A2/GLC or B8/RAK-reactive T cells producing IFN-g in response to specific peptide antigen was significantly lower in RA patients than controls. The A2/GLC or B8/RAK tetramer-positive T cells were also substantially enriched in CD28-CD27- T cells of a late-differentiated phenotype in RA patients but not in controls.
CONCLUSION: RA patients show clonal expansion of dysfunctional, terminally differentiated CD8+ EBV-specific T cells in their T cell responses to immunodominant lytic peptide EBV epitopes, which could be a sign of specific impairment of virus-host interactions in RA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15693083

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

1.  In ACPA-positive RA patients, antibodies to EBNA35-58Cit, a citrullinated peptide from the Epstein-Barr nuclear antigen-1, strongly cross-react with the peptide β60-74Cit which bears the immunodominant epitope of citrullinated fibrin.

Authors:  M Cornillet; E Verrouil; A Cantagrel; G Serre; L Nogueira
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  T cell replicative senescence in human aging.

Authors:  Jennifer P Chou; Rita B Effros
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

3.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

Review 4.  The role of the Epstein-Barr virus in the pathogenesis of some autoimmune disorders - Similarities and differences.

Authors:  G Füst
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-12-23

5.  Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis.

Authors:  Jan D Lünemann; Oliver Frey; Thorsten Eidner; Michael Baier; Susanne Roberts; Junji Sashihara; Rudolf Volkmer; Jeffrey I Cohen; Gert Hein; Thomas Kamradt; Christian Münz
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

Review 6.  Epstein-Barr virus and rheumatoid arthritis: is there a link?

Authors:  Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Res Ther       Date:  2006-01-16       Impact factor: 5.156

7.  Isotypes of Epstein-Barr virus antibodies in rheumatoid arthritis: association with rheumatoid factors and citrulline-dependent antibodies.

Authors:  Marie Wulff Westergaard; Anette Holck Draborg; Lone Troelsen; Søren Jacobsen; Gunnar Houen
Journal:  Biomed Res Int       Date:  2015-04-27       Impact factor: 3.411

8.  Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies.

Authors:  Corinne Miceli-Richard; Nicolas Gestermann; Corinne Amiel; Jérémie Sellam; Marc Ittah; Stephan Pavy; Alejandra Urrutia; Isabelle Girauld; Guislaine Carcelain; Alain Venet; Xavier Mariette
Journal:  Arthritis Res Ther       Date:  2009-05-26       Impact factor: 5.156

Review 9.  Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation.

Authors:  Andreas Lossius; Jorunn N Johansen; Øivind Torkildsen; Frode Vartdal; Trygve Holmøy
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

Review 10.  High avidity autoreactive T cells with a low signalling capacity through the T-cell receptor: central to rheumatoid arthritis pathogenesis?

Authors:  Ranjeny Thomas; Malcolm Turner; Andrew P Cope
Journal:  Arthritis Res Ther       Date:  2008-07-24       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.